Q-omics provides the consensus-scored TRABD2A profile across patient tissues and cancer cell-line models. TRABD2A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TRABD2A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TRABD2A RNA expression shows 16,799 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, THCA, and LSCC as cancer lineages where TRABD2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRABD2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRABD2A survival associations across molecular data types. TRABD2A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRABD2A RNA expression–survival associations across cancer types. High TRABD2A expression shows unfavorable associations in MESO, GBM and KIRC, but favorable associations in THCA, UVM and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TRABD2A RNA expression.
This table summarizes TRABD2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRABD2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRABD2A shows lower tumor expression in LUSC and higher tumor expression in THCA, HNSC, STAD, KIRP and KIRC. The THCA box plot shows higher TRABD2A RNA expression in tumor versus normal tissue (log2 FC = +1.333, t-test p < 0.001).
This table shows molecular features associated with TRABD2A in patient tissues and cancer cell lines. In patient samples, TRABD2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRABD2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
